Group 1 - Jilin Aodong (000623) participated in an investor relations event to enhance communication between investors and the company, showcasing its business scope which includes traditional Chinese medicine, chemical drugs, and health products [1] - The company has 628 production approval numbers, with 315 for traditional Chinese medicine, and aims to leverage its brand and product quality to enhance market value and sales of key products [1] - Jilin Aodong plans to cultivate multiple core products with over 100 million yuan in sales and accelerate the development of strategic products with a market potential of 10 billion yuan [1] Group 2 - The Yanbian Pharmaceutical project has completed several production facilities, which passed GMP compliance checks and are now contributing to revenue [2] - In 2024, the health business is expected to generate 212 million yuan in sales, accounting for 8.13% of total revenue, with over 200 health products produced and sold [2] - The company has 22 registered health food certificates and 85 filing certificates, with 43 products generating over 1 million yuan in sales [2] Group 3 - Jilin Aodong is enhancing brand awareness through diverse marketing strategies, including e-commerce and social media platforms like Douyin [3] - The company is focusing on the core value of traditional Chinese medicinal materials and aims to develop high-value projects through research and innovation [3] - The health product development system is driven by consumer health trends, emphasizing research and development of functional health products [3] Group 4 - The company is investing in core quality long-term equity securities and related pharmaceutical companies, collaborating with various funds to invest in biopharmaceuticals and internet healthcare [4] - Jilin Aodong aims to strengthen its research capabilities through indirect investments in distinctive and competitive biopharmaceutical projects [4] - The company is optimizing its financial asset allocation to create a positive cycle of financial capital supporting real industry growth [4]

编号：2025-005 | | √特定对象调研□分析师会议 | | --- | --- | | 投资者关系活 动类别 | □媒体采访□业绩说明会 | | | □新闻发布会□路演活动 | | | √现场参观 | | | □其他（请文字说明其他活动内容） | | | 现场参观调研 | | 参与单位名称 | 国泰海通证券投资者教育基地、全景投资者教育上海基地、工 | | 及人员姓名 | 商银行、奇迹基金、中创投资、亚东投资、琢磨基金、探普资 | | | 产、上海磬晟投资及个人投资者 | | 时间 | 2025 年 7 月 4 日 | | 地点 | 吉林省敦化市敖东大街 2158 号 | | 上市公司接待 | 副董事长、总经理：郭淑芹 | | | 董事、副总经理：杨凯 | | | 董事、副总经理、财务总监：张淑媛 | | 人员姓名 | 董事、副总经理、董事会秘书：王振宇 | | | 董事、党委书记：赵大龙 | | | 副总经理：林晓林 | | | 由国泰海通证券、全景网主办的"吉聚资本 鹿鸣东方—走 | | | 进上市公司"主题活动走进吉林敖东，通过与企业家面对面交 | | | 流、实地走访的形式，让投资者更加深入全 ...